MGMT and glioblastoma: The CHK1 inhibitor SRA737 abolishes the TMZ-induced structural remodeling of LINC01956 and subsequent MGMT upregulation, consequently resensitizing TMZ-resistant MGMT promoter-methylated GBM to TMZ [75].